AngioDynamics, Inc. (ANGO)
Market Cap | 361.24M |
Revenue (ttm) | 292.73M |
Net Income (ttm) | -243.03M |
Shares Out | 40.63M |
EPS (ttm) | -6.02 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 541,524 |
Open | 8.52 |
Previous Close | 8.58 |
Day's Range | 8.52 - 8.96 |
52-Week Range | 5.26 - 9.58 |
Beta | 0.67 |
Analysts | Strong Buy |
Price Target | 12.00 (+34.98%) |
Earnings Date | Jan 8, 2025 |
About ANGO
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergen... [Read more]
Financial Performance
In 2024, AngioDynamics's revenue was $303.91 million, a decrease of -10.28% compared to the previous year's $338.75 million. Losses were -$184.35 million, 251.5% more than in 2023.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ANGO stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 34.98% from the latest price.
News
AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO) Q1 2025 Earnings Conference Call October 3, 2024 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vic...
AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday
U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday.
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings
AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3.
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Participate in Upcoming Investor Conferences
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics: Lumpy Progress Is Still Progress
AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day, as the company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Auryon and NanoKnife gene...
Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16.
AngioDynamics (ANGO) Q4 2024 Earnings Call Transcript
AngioDynamics Inc. (NASDAQ:ANGO) Q4 2024 Earnings Conference Call July 16, 2024 8:00 AM ET Company Participants Jim Clemmer - President & CEO Stephen Trowbridge - EVP & CFO Conference Call Participan...
AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaV...
AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript
AngioDynamics Inc. (NASDAQ:ANGO) Q3 2024 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants Jim Clemmer - President, Chief Executive Officer Steve Trowbridge - Executive Vice Pres...
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on Febru...
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...